Supplementary Materials
The PDF file includes:
- Materials and Methods
- Fig. S1. Cross-reactivity test of murine TNFR2 antibodies to other TNF superfamily receptors.
- Fig. S2. Enhanced proliferation and activation of T cells mediated by higher-order TNFR2 cross-linking for Y9 costimulation in vitro.
- Fig. S3. In vitro Treg suppression assay.
- Fig. S4. In vivo activity of Y9 and anti–PD-L1 combination.
- Fig. S5. Ligand blocking of Y9-DANA.
- Fig. S6. Impact of treatment with Y9 on different immune cell subsets.
- Fig. S7. Ex vivo analysis of tumor-specific CD8+ T cell responses.
- Fig. S8. Impact of treatment with Y9 on frequency changes in the T cell compartment.
- Fig. S9. Characterization of the tumor-associated myeloid compartment after anti-TNFR2 treatment.
- Fig. S10. Additional data for toxicity profile of long-term exposure to anti-TNFR2 or anti–CTLA-4 antibodies in BALB/c and C57BL/6 mice.
- Fig. S11. Serum cytokine data for toxicity profile of long-term exposure to anti-TNFR2 or anti–CTLA-4 antibodies in BALB/c and C57BL/6 mice and toxicity study in EMT6 tumor-bearing mice.
- Fig. S12. Repeat toxicity study with anti–PD-1 combinations.
- Fig. S13. TNFR2 receptor constructs used for epitope mapping and binding studies.
- Fig. S14. High-resolution epitope mapping of human and mouse anti-TNFR2 antibodies.
- Fig. S15. Gating strategy of mouse T cells in the tdLN and tumor.
- Table S1. Description of chimeric TNFR2 constructs.
- Table S2. Sequences of murine TNFR2 antibodies.
- Table S3. Murine T cell flow cytometry antibodies.
- Table S4. Human T cell flow cytometry antibodies.
- References (52, 53)
Other Supplementary Material for this manuscript includes the following:
- Data file S1 (Microsoft Excel format). Primary data.